AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 14, 2022 | Grant | €2.50M | 1 |
European Innovation Council
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
European Innovation Council
|
Yes | Grant |